Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week

Odyssey Therapeutics, Inc.

Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.
Cash, cash equivalents and marketable securities $433.1M as of June 30, 2026; expected to fund operations into 2H 2028.
R&D expenses $36.2M (up from $30.2M); G&A $10.5M (down from $13.2M).
OD-001 Phase 2a data accepted for oral presentation at UEG Week in October; Phase 2b monotherapy and Phase 2a combo with vedolizumab expected to initiate in 2H 2026.
OD-002 (SLC15A4 inhibitor) CTA filing expected in 2H 2026; Phase 1/2a trial initiation in 1H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.